Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Liver Diseases

  Free Subscription

Articles published in J Clin Oncol

Retrieve available abstracts of 24 articles:
HTML format

Single Articles

    June 2022
  1. BEJJANI AC, Finn RS
    Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations.
    J Clin Oncol. 2022 Jun 1:JCO2102605. doi: 10.1200/JCO.21.02605.
    PubMed     Abstract available

    May 2022
  2. CHIANG CH, Chiang CH, Chiang CH
    Are H1-Antihistamines Associated With a Lower Risk of Hepatocellular Carcinoma?
    J Clin Oncol. 2022 May 12:JCO2200179. doi: 10.1200/JCO.22.00179.

    March 2022
  3. SUTCUOGLU O, Ulas Kahya B, Ozdemir N, Yazici O, et al
    Can Systemic Control Be Achieved in the Treatment of Oligometastatic Hepatocellular Cancer With Hepatic Artery Infusion Fluorouracil, Leucovorin, and Oxaliplatin Treatment?
    J Clin Oncol. 2022 Mar 29:JCO2200047. doi: 10.1200/JCO.22.00047.

  4. JOHNSON PJ, Pinato DJ, Kalyuzhnyy A, Toyoda H, et al
    Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma.
    J Clin Oncol. 2022 Mar 28:JCO2102373. doi: 10.1200/JCO.21.02373.

  5. MEI J, Yu H, Qin L, Jia Z, et al
    FOLFOX-HAIC for Unresectable Large Hepatocellular Carcinoma: The Effectiveness Has Yet to be Determined.
    J Clin Oncol. 2022 Mar 22:JCO2102533. doi: 10.1200/JCO.21.02533.

    January 2022
  6. SHEN YC, Hsu HC, Lin TM, Chang YS, et al
    H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection.
    J Clin Oncol. 2022 Jan 19:JCO2101802. doi: 10.1200/JCO.21.01802.
    PubMed     Abstract available

    December 2021
  7. LYU N, Wang X, Li JB, Lai JF, et al
    Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    J Clin Oncol. 2021 Dec 14:JCO2101963. doi: 10.1200/JCO.21.01963.
    PubMed     Abstract available

  8. MULCAHY MF, Mahvash A, Pracht M, Montazeri AH, et al
    Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial.
    J Clin Oncol. 2021;39:3897-3907.
    PubMed     Abstract available

  9. TROBAUGH-LOTRARIO A, Katzenstein HM, Ranganathan S, Lopez-Terrada D, et al
    Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee.
    J Clin Oncol. 2021 Dec 7:JCO2100803. doi: 10.1200/JCO.21.00803.
    PubMed     Abstract available

  10. SALEM R
    Hepatic Arterial Infusion Chemotherapy for Large Hepatocellular Carcinoma: Ready for Prime Time?
    J Clin Oncol. 2021 Dec 2:JCO2102392. doi: 10.1200/JCO.21.02392.

    October 2021
  11. LI QJ, He MK, Chen HW, Fang WQ, et al
    Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.
    J Clin Oncol. 2021 Oct 14:JCO2100608. doi: 10.1200/JCO.21.00608.
    PubMed     Abstract available

    September 2021
  12. BOOTH CM, Berry SR
    Perioperative Chemotherapy for Resectable Liver Metastases in Colorectal Cancer: Do We Have a Blind Spot?
    J Clin Oncol. 2021 Sep 24:JCO2101972. doi: 10.1200/JCO.21.01972.

  13. LENTZ RW, Messersmith WA
    Transarterial Radioembolization in Patients With Unresectable Colorectal Cancer Liver Metastases.
    J Clin Oncol. 2021 Sep 20:JCO2101993. doi: 10.1200/JCO.21.01993.

  14. KANEMITSU Y, Shimizu Y, Mizusawa J, Inaba Y, et al
    Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial.
    J Clin Oncol. 2021 Sep 14:JCO2101032. doi: 10.1200/JCO.21.01032.
    PubMed     Abstract available

  15. RAYSON D
    J Clin Oncol. 2021;39:2962-2963.

    July 2021
  16. KELLEY RK, Sangro B, Harris W, Ikeda M, et al
    Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
    J Clin Oncol. 2021 Jul 22:JCO2003555. doi: 10.1200/JCO.20.03555.
    PubMed     Abstract available

    June 2021
  17. QIN S, Bi F, Gu S, Bai Y, et al
    Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
    J Clin Oncol. 2021 Jun 29:JCO2100163. doi: 10.1200/JCO.21.00163.
    PubMed     Abstract available

    November 2020
  18. GORDAN JD, Kennedy EB, Abou-Alfa GK, Beg MS, et al
    Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.
    J Clin Oncol. 2020 Nov 16:JCO2002672. doi: 10.1200/JCO.20.02672.
    PubMed     Abstract available

    September 2020
  19. TANG W, Ren L, Liu T, Ye Q, et al
    Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial.
    J Clin Oncol. 2020;38:3175-3184.
    PubMed     Abstract available

  20. CHAO C, Bhatia S, Xu L, Cannavale KL, et al
    Chronic Comorbidities Among Survivors of Adolescent and Young Adult Cancer.
    J Clin Oncol. 2020;38:3161-3174.
    PubMed     Abstract available

    July 2020
  21. FINN RS, Ikeda M, Zhu AX, Sung MW, et al
    Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
    J Clin Oncol. 2020 Jul 27:JCO2000808. doi: 10.1200/JCO.20.00808.
    PubMed     Abstract available

    May 2020
  22. HIYAMA E, Hishiki T, Watanabe K, Ida K, et al
    Outcome and Late Complications of Hepatoblastomas Treated Using the Japanese Study Group for Pediatric Liver Tumor 2 Protocol.
    J Clin Oncol. 2020 May 18:JCO1901067. doi: 10.1200/JCO.19.01067.
    PubMed     Abstract available

  23. LEVY EB, Fiel MI, Hamilton SR, Kleiner DE, et al
    State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach.
    J Clin Oncol. 2020;38:1633-1640.
    PubMed     Abstract available

    October 2019
  24. MODEST DP, Martens UM, Riera-Knorrenschild J, Greeve J, et al
    FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).
    J Clin Oncol. 2019 Oct 14:JCO1901340. doi: 10.1200/JCO.19.01340.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.